Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 30,000 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 30,000 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $3.68, for a total transaction of $110,400.00. Following the sale, the director owned 6,169,863 shares in the company, valued at $22,705,095.84. This represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, May 5th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.52, for a total transaction of $105,600.00.
• On Tuesday, April 7th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.10, for a total transaction of $93,000.00.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX traded up $0.33 during mid-day trading on Thursday, hitting $3.80. 38,573,526 shares of the company’s stock traded hands, compared to its average volume of 17,309,813. The company’s 50-day moving average is $3.29 and its two-hundred day moving average is $3.82. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47. The company has a market capitalization of $2.01 billion, a P/E ratio of -3.17 and a beta of 1.04. Recursion Pharmaceuticals, Inc. has a 1 year low of $2.77 and a 1 year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.08. The firm had revenue of $6.47 million for the quarter, compared to analysts’ expectations of $15.78 million. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The business’s revenue was down 56.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.50) EPS. On average, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on RXRX shares. Wall Street Zen cut shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Needham & Company LLC restated a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. JPMorgan Chase & Co. cut their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Finally, Morgan Stanley upped their price target on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $8.10.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. ARK Investment Management LLC grew its holdings in Recursion Pharmaceuticals by 1.7% during the 3rd quarter. ARK Investment Management LLC now owns 33,545,499 shares of the company’s stock valued at $163,702,000 after purchasing an additional 556,868 shares during the last quarter. Vanguard Group Inc. grew its holdings in Recursion Pharmaceuticals by 10.3% during the 3rd quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock valued at $194,127,000 after purchasing an additional 3,708,975 shares during the last quarter. Rafferty Asset Management LLC grew its holdings in Recursion Pharmaceuticals by 110.6% during the 3rd quarter. Rafferty Asset Management LLC now owns 750,191 shares of the company’s stock valued at $3,661,000 after purchasing an additional 394,022 shares during the last quarter. DNB Asset Management AS bought a new position in Recursion Pharmaceuticals during the 3rd quarter valued at about $1,531,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in Recursion Pharmaceuticals by 94.8% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 1,774,995 shares of the company’s stock valued at $8,662,000 after buying an additional 863,910 shares during the period. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.